Provided by Tiger Trade Technology Pte. Ltd.

Intensity Therapeutics, Inc.

4.74
-0.1200-2.47%
Volume:15.77K
Turnover:73.48K
Market Cap:15.48M
PE:-0.99
High:4.84
Open:4.57
Low:4.57
Close:4.86
52wk High:43.50
52wk Low:3.51
Shares:3.26M
Float Shares:3.04M
Volume Ratio:1.07
T/O Rate:0.52%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.8026
EPS(LYR):-8.5567
ROE:-195.88%
ROA:-89.91%
PB:1.68
PE(LYR):-0.55

Loading ...

Intensity Therapeutics announces annual shareholder meeting webcast

Reuters
·
May 01

Intensity Therapeutics Inc : Benchmark Adjusts Target Price to $12 From $1.50 to Reflect Reverse Stock Split

THOMSON REUTERS
·
Mar 31

U.S. Tariff and Trade Policy Risks Threaten Intensity Therapeutics’ Supply Chain, Costs, and Stock Valuation

TIPRANKS
·
Mar 29

Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update

THOMSON REUTERS
·
Mar 28

Intensity Therapeutics FY2025 net loss narrows 28.66% to $(11.6) million; operating expenses drop 27.81% to $12.0 million

Reuters
·
Mar 28

Intensity Therapeutics issued new patent in the US

TIPRANKS
·
Mar 24

Intensity Therapeutics wins US patent 12,496,345 for cancer treatment method

Reuters
·
Mar 24

Intensity Therapeutics Inc Files for Common Stock Offering of up to $60 Mln - SEC Filing

THOMSON REUTERS
·
Mar 24

Intensity Therapeutics expands ATM equity offering capacity to USD 60 million

Reuters
·
Mar 24

Intensity Therapeutics Inc - Expanded Atm Facility Intended to Enhance Financial Flexibility - SEC Filing

THOMSON REUTERS
·
Mar 24

Alliance Global Partners Sticks to Their Buy Rating for Intensity Therapeutics, Inc. (INTS)

TIPRANKS
·
Mar 13

BUZZ-U.S. STOCKS ON THE MOVE -Natera, Pacira BioSciences, Kezar Life Sciences

Reuters
·
Mar 12

Intensity Therapeutics Updates Breast Cancer Trial, Files To Resume Enrollment Following Study Pause

Benzinga
·
Mar 12

BUZZ-Intensity Therapeutics rises as breast cancer drug shows early promise

Reuters
·
Mar 12

Intensity Therapeutics reports 71% pCR in INT230-6 arm and 44% fewer grade 3+ adverse events in INVINCIBLE-4 study

Reuters
·
Mar 12

Intensity Therapeutics Inc - Protocol Amendment Proposes Lower Drug Volume and Single Int230-6 Injection

THOMSON REUTERS
·
Mar 12

Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer Invincible-4 Study

THOMSON REUTERS
·
Mar 12

Intensity Therapeutics Inc - Submits Protocol Amendment to Swissmedic and Swiss Ethics Committee to Resume Invincible-4 Study Enrollment

THOMSON REUTERS
·
Mar 12

Intensity Therapeutics Inc - Preliminary Invincible-4 Study Shows 71.4% Pcr With Int230-6 Plus Soc, 33% With Soc Alone

THOMSON REUTERS
·
Mar 12

Intensity Therapeutics regains Nasdaq compliance

TIPRANKS
·
Mar 06